CJJ300

Item no.	HY-146693-100mg
Manufacturer	MedChem Express
CASRN	1807631-83-9
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.77
Formula	C30H33N3
Citations	[1]Han Wu, et al. The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020 Mar 1;189:112042.
Smiles	CC1=C(C(C)=C(C(C)=C1CNC2=CC=CC=C2)CNC3=CC=CC=C3)CNC4=CC=CC=C4
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	TGF-β Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	435.60
Product Description	CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 μM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway	TGF-beta/Smad
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-146693-100mg-safety-datasheet.pdf